Biologic therapies in systemic lupus erythematosus.

about

Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus Childhood Lupus--Diagnosis and Management.

P2860

Q32181985-BAD7BFA3-F447-436A-9BC4-D4128A1CF552 Q38686357-858CE84A-1927-4876-9E11-1B17E21D0AAD

P2860

Biologic therapies in systemic lupus erythematosus.

Item

http://www.wikidata.org/entity/Q38425831

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biologic therapies in systemic lupus erythematosus.

@en

type

Item

label

Biologic therapies in systemic lupus erythematosus.

@en

prefLabel

Biologic therapies in systemic lupus erythematosus.

@en

P1476

Biologic therapies in systemic lupus erythematosus.

@en

P2093

Christine B Bernal

http://www.w3.org/2001/XMLSchema#string

Leonid D Zamora

http://www.w3.org/2001/XMLSchema#string

Sandra V Navarra

http://www.w3.org/2001/XMLSchema#string

P2860

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.

P304

146-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1756-185X.12490

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25884458

http://www.w3.org/2001/XMLSchema#string

Biologic therapies in systemic lupus erythematosus.

about

P2860

P2860

Biologic therapies in systemic lupus erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698